

AMENDMENTS TO THE SPECIFICATION

Please replace paragraph [0013] with the following paragraph:

[0013] Preferably, Xad represents the following peptide sequence -Lys-Arg-Arg-Gly-Tyr-Lys-Gly-Gly-His- (SEQ ID NO:41) or Leu-Leu-Arg-Gly-Tyr-Lys-Gly-Gly-His- (SEQ ID NO:49).

Please replace paragraph [0017] with the following paragraph:

[0017] Preferably, Xac represents the following peptide sequence -Asn-Gly-Glu- (SEQ ID NO:50) or Ala-Ala-Glu- (SEQ ID NO:51).

Please replace paragraph [0022] with the following paragraph:

[0022] According to a more preferred embodiment of the invention, Xaa represents the following peptide sequence NH₂-Asp-Lys-Leu-Ile-Gly-Ser- (SEQ ID NO:46) or NH₂-Ala-Ala-Ala-Ala-Gly-Ser- (SEQ ID NO:52), and/or Xab represents the following peptide sequence -Val-Trp-Gly-Ala-Val-Asn-Tyr-Thr-Ser-Asp- (SEQ ID NO:47), and/or Xae represents the following peptide sequence -Gly-Ser-Phe-Ala-Asn-Val-Asn- (SEQ ID NO:48), and/or Xaf represents the following amino acid -Trp- and/or Xag represents the following peptide sequence -Glu-Thr-OH or -Arg-Thr-OH.

Please replace paragraph [0031] with the following paragraph:

[0031] The fusion peptide "MF α 1/heliomicine" with the five residues of the propeptide of factor MF α 1(Ser-Leu-Asp-Lys-Arg) (SEQ ID NO:53), which are situated at the N-terminal position,

and its coding sequence are part of the present invention, described in particular by the sequence identifier No. 1 (SEQ ID NO:1), corresponding to amino acids 1 to 49.

Please replace the sequence listing with the substitute sequence listing attached herewith.